Pharma Report Winter 2018 from Haavind
We are once again proud to present the newest edition of our biannual pharma report. The report looks more closely at some of the legal developments in the pharmaceutical sector in Norway, which occurred in the second part of 2017.
We are once again proud to present the newest edition of our biannual pharma report. The report looks more closely at some of the legal developments in the pharmaceutical sector in Norway, which occurred in the second part of 2017.
In this edition, you can read about several patent cases, including the buprenorphine case which involved practitioners from our law firm. You can also find out whether GlaxoSmithKline succeeded in acquiring trademark protection for the color purple. In addition, you can read about the Norwegian Board of Health Supervision’s take on off-label practice, as well as other regulatory developments.
Read the Pharma Report Winter 2018 here (e-book)
Download the Pharma Report Winter 2018 here (PDF, 12MB)
Our Healthcare and Life Science team continuously and closely monitors legal developments in Norway relevant for the pharmaceutical sector. If you wish to discuss how your business can meet the legal challenges of this innovative and highly regulated sector, you are always welcome to contact us.
